- Home
- RIVN vs BIIB Comparison
RIVN vs BIIB Comparison
Compare RIVN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIVN
- BIIB
- Stock Information
- Founded
- RIVN 2009
- BIIB 1978
- Country
- RIVN United States
- BIIB United States
- Employees
- RIVN N/A
- BIIB N/A
- Industry
- RIVN Auto Manufacturing
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- RIVN Consumer Discretionary
- BIIB Health Care
- Exchange
- RIVN Nasdaq
- BIIB Nasdaq
- Market Cap
- RIVN 16.6B
- BIIB 18.7B
- IPO Year
- RIVN 2021
- BIIB 1991
- Fundamental
- Price
- RIVN $14.11
- BIIB $144.87
- Analyst Decision
- RIVN Hold
- BIIB Buy
- Analyst Count
- RIVN 19
- BIIB 27
- Target Price
- RIVN $14.00
- BIIB $188.09
- AVG Volume (30 Days)
- RIVN 51.0M
- BIIB 1.5M
- Earning Date
- RIVN 11-06-2025
- BIIB 10-29-2025
- Dividend Yield
- RIVN N/A
- BIIB N/A
- EPS Growth
- RIVN N/A
- BIIB 31.67
- EPS
- RIVN N/A
- BIIB 10.45
- Revenue
- RIVN $5,151,000,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- RIVN $8.59
- BIIB $2.00
- Revenue Next Year
- RIVN $30.94
- BIIB N/A
- P/E Ratio
- RIVN N/A
- BIIB $13.83
- Revenue Growth
- RIVN 2.73
- BIIB 3.36
- 52 Week Low
- RIVN $9.50
- BIIB $110.04
- 52 Week High
- RIVN $17.15
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- RIVN 58.17
- BIIB 60.19
- Support Level
- RIVN $12.57
- BIIB $141.12
- Resistance Level
- RIVN $14.65
- BIIB $147.23
- Average True Range (ATR)
- RIVN 0.78
- BIIB 4.65
- MACD
- RIVN 0.03
- BIIB 0.23
- Stochastic Oscillator
- RIVN 62.60
- BIIB 71.16
About RIVN Rivian Automotive Inc.
Rivian Automotive Inc is an automotive manufacturer that develops and builds electric vehicles ("EVs") as well as software and services. It launches its consumer vehicle business with the R1 platform consisting of two vehicles: the R1T, and the R1S. The company has two reportable segments: Automotive, which derives the majority of revenue, and Software and Services segment. The Automotive reportable segment derives its revenues and cost of revenues from the production and sale of new EVs and the sale of regulatory credits generated by the production and sale of EVs. The Software and services reportable segment derives its revenues and cost of revenues from remarketing, vehicle repair and maintenance services, and vehicle electrical architecture and software development services.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.